Trial Search Results
A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa
The purpose of this study is to evaluate how safe and effective ABI-009 is for people with advanced malignant PEComa. ABI-009, human albumin-bound rapamycin, is an investigational agent to treat patients with PEComa in this study, which has not been approved for the treatment of malignant PEComa; there are no drugs currently approved for this indication. Rapamycin, the active ingredient, inhibits a biological pathway known to be dysregulated in PEComa cancer cells. Rapamycin and similar type oftherapeutics have been used in various other tumors, including advanced renal cell carcinoma. The human albumin component of ABI-009 may allow rapamycin to reach cancer cells more effectively.
Stanford is currently not accepting patients for this trial.
- Drug: ABI-009
1. Patients must have a histologically confirmed diagnosis of malignant PEComa that is
either metastatic or locally advanced and for which surgery is not a recommended
2. Patients must have available tumor block along with the corresponding pathology report
(or approximately 30 unstained slides, with a minimum of 16 slides), and/or fresh
biopsy to allow retrospective centralized confirmation of malignant PEComa and for
mTOR pathway analysis and biomarker analysis.
3. Patients must have one or more measurable target lesions by CT scan or MRI. Measurable
disease by RECIST v1.1.
4. Patients must not have been previously treated with an mTOR inhibitor.
5. Prior treatment (investigational or other), chemotherapy, radiotherapy, surgery, or
other therapeutic agents (except mTOR inhibitors) is allowed, if completed after 5
half-lives or ≥28 days prior to enrollment, whichever is shorter.
6. Eligible patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG)
performance status 0 or 1.
7. Patients must have the following blood chemistry levels at screening (obtained
≤14 days prior to enrollment (local laboratory):
1. total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dl
2. AST ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases)
3. serum creatinine ≤1.5 x ULN
8. Adequate biological parameters as demonstrated by the following blood counts at
screening (obtained ≤14 days prior to enrollment, local laboratory):
1. Absolute neutrophil count (ANC) ≥1.5 × 109/L;
2. Platelet count ≥100,000/mm3 (100 × 109/L);
3. Hemoglobin ≥9 g/dL.
9. Serum triglyceride <300 mg/dL; serum cholesterol < 350 mg/dL.
10. Male or non-pregnant and non-breast feeding female:
- Females of child-bearing potential must agree to use effective contraception
without interruption from 28 days prior to starting IP and while on study
medication and have a negative serum pregnancy test (β -hCG) result at screening
and agree to ongoing pregnancy testing during the course of the study, and after
the end of study treatment.
- Male patients must practice abstinence or agree to use a condom during sexual
contact with a pregnant female or a female of childbearing potential while
participating in the study, even if he has undergone a successful vasectomy.
11. Life expectancy of >3 months, as determined by the investigator.
12. Ability to understand and sign informed consent.
13. Willingness and ability to comply with scheduled visits, laboratory tests, and other
A patient will not be eligible for inclusion in this study if any of the following criteria
1. Patients with lymphangioleiomyomatosis (LAM) are excluded.
2. Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A
patient with controlled and asymptomatic CNS metastases may participate in this study.
As such, the patient must have completed any prior treatment for CNS metastases ≥28
days (including radiotherapy and/or surgery) prior to start of treatment in this study
and should not be receiving chronic corticosteroid therapy for the CNS metastases.
3. Active gastrointestinal bleeding, if transfusion dependent.
4. Pre-existing thyroid abnormality is allowed provided thyroid function can be
controlled with medication.
5. Uncontrolled serious medical or psychiatric illness. Patients with a "currently
active" second malignancy other than non-melanoma skin cancers, carcinoma in situ of
the cervix, resected incidental prostate cancer (staged pT2 with Gleason Score ≤ 6 and
postoperative PSA <0.5 ng/mL), or other adequately treated carcinoma-in-situ are
ineligible. Patients are not considered to have a "currently active" malignancy if
they have completed therapy and are free of disease for ≥1 year).
6. Liver-directed therapy within 2 months of enrollment. Prior treatment with
radiotherapy (including radio-labeled spheres and/or cyberknife, hepatic arterial
embolization (with or without chemotherapy) or cyrotherapy/ablation) is allowed if
these therapies did not affect the areas of measurable disease being used for this
7. Recent infection requiring systemic anti-infective treatment that was completed
≤14 days prior to enrollment (with the exception of uncomplicated urinary tract
infection or upper respiratory tract infection).
8. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy.
9. Unstable coronary artery disease or myocardial infarction during preceding 6 months.
10. Receiving any concomitant antitumor therapy.
11. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary
12. The use of certain medications and illicit drugs within 5 half-lives or 28 days,
whichever is shorter prior to the first dose of study drug and for the duration of the
study will not be allowed.
13. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving
the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with
narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,
dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to
receiving the first dose of ABI-009.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study